ASH Clinical News August 2015_updated | Page 15

Speak with your patients about
how NovoSeven® RT may fit into
their lifestyle.

Fast to access—
room temperature stable1

a

Provides low
infusion volume1,a

Based on an 88-kg patient receiving a single dose
of NovoSeven® RT (90 mcg/kg) for a joint bleed.

Adverse Reactions
• The most common and serious adverse reactions in clinical trials
are thrombotic events. Thrombotic adverse reactions following the
administration of NovoSeven® RT in clinical trials occurred in 4% of
patients with acquired hemophilia and 0.2% of bleeding episodes
in patients with congenital hemophilia.
Drug Interactions
• Thrombosis may occur if NovoSeven® RT is administered
concomitantly with Coagulation Factor XIII.
Please see Brief Summary of Prescribing Information
on the following page.
Reference: 1. NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2015.

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.
NovoSeven® is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2015 Novo Nordisk
All rights reserved. 0515-00027211-1
August 2015

Infusion takes
just 2 to 5 minutes1,a

Hear from Bob and other patients at
NovoSevenRT.com/hcp/SpeakUp